



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/026,914	12/27/2001	Birgit Linhart	0273-0006	6890

7590 06/15/2006

Toni-Junell Herbert
REED SMITH
3110 Fairview Park Drive
Suite1400
Falls Church, VA 22042

EXAMINER

HINES, JANA A

ART UNIT PAPER NUMBER

1645

DATE MAILED: 06/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/026,914	Applicant(s) LINHART ET AL.	
	Examiner Ja-Na Hines	Art Unit 1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 March 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 7,9,22-25 and 36-51 is/are pending in the application.
- 4a) Of the above claim(s) 7,9,22-25,36-41 and 44 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 42, 43 and 45-51 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Amendment Entry

1. The amendment filed March 28, 2006 has been entered. Claims 1-6, 8, 10-21 and 26-35 have been cancelled. Claims 7, 9 and 22-25 have been withdrawn. Claims 36-51 have been newly added.

Election/Restrictions

2. Newly submitted claims 36-41 and 44 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: Claims 36-42 are drawn to a method of identifying plant hybrid allergens and claim 44 is drawn to a method of treating IgE-mediated hypersensitivity. The methods are independent and distinct from the originally elected group drawn to the hybrid polypeptide, pharmaceutical composition and the method of preparation.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 36-41 and 44 have been withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

3. Therefore, claims 42-43 and 45-51 are under consideration in this office action.

Withdrawal of Rejections

4. The following rejections have been withdrawn in view of applicants' amendments:

a) The written description rejection of claims 1-6, 13-15, 20-21, 27-29 and 30-35 under 35 U.S.C. 112, first paragraph;

Art Unit: 1645

- b) The new matter rejection of claims 1-6, 13-15, 20-21 and 26-35 under 35 U.S.C. 112, first paragraph; and
- c) The enablement rejection of claims 1-6, 13-15, 20-21 and 26-35 under 35 U.S.C. 112, first paragraph.

Response to Arguments

5. Applicant's arguments filed March 28, 2006 have been fully considered but they are not persuasive.

New Grounds Of Rejection

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 42-43, 45 and 50-51 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

The specification and claims lack sufficient written description of a method of preparing hybrid plant fusion polypeptides and the instantly claimed polypeptides or the pharmaceutical compositions comprising them.

Applicants' urge that there is written description for the instantly claimed method. Applicants point to using purified recombinant timothy grass pollen allergens as the basis of their invention. However the claims do not require the use of timothy grass pollen allergens, rather the claims are generic and drawn to an unidentified polynucleotide encoding a plant fusion polypeptide. There is only a discussion of timothy grass pollen allergens, there is no discussion of the generic polynucleotide encoding a plant fusion polypeptide. Applicants' assert that specific allergen have been isolated and sequenced and that the instant invention teaches and claims a hybrid polypeptide comprising those allergens. However, the instant claims encompass significantly more than just the timothy grass pollen allergens or even a specific allergen. Only claims 46-48 and 51 specific timothy grass allergens. There is no limitation on which plant allergens nor do the claims only encompass the timothy grass allergens. The examples are limited to Phl p1,2, 5 and 6. The claims are significantly broader than applicants' contention and support. Thus the invention is drawn to absolutely any plant allergens and any modification or fragment, yet there is no written description of such hybrid polypeptides. Therefore, this argument is not persuasive, since it does not overcome the written description issue.

Applicants' believe they have limited their allergens to those that induce IgE blocking antibodies *in vivo* and have reduced allergenicity when compared to wild-type allergens. However, claims 42-43 are drawn to a method of preparation, and the administration does not add a limitation to the method of preparation. Claims 45-51 are drawn to products. The recitation of how the agents are to be identified does not add

any limitation to the product. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production.

Applicants' assert that by amending the claims to recite the function of inducing an antibody response the rejection is now moot. However the specification only describes recombinant timothy grass pollen allergens; there is no description of any other type of allergen, nor is there any description of a hybrid polypeptide comprising any other type of plant allergen. Thus, the written description is not commensurate in scope to what is being instantly claimed. Furthermore, applicants' have failed to provide any guidance concerning the missing information. Thus, applicants' discussion of the specific timothy grass pollen allergens is not sufficient since the hybrid polypeptide is described only by a functional characteristic, without any disclosed correlation between function and structure of the sequence, it is not sufficient characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence. It is unquestionable that the claims are broadly generic with respect all possible allergens encompassed by the claims. The possible structural variations are limitless, thus a hybrid polypeptide described only by a functional characteristic, fails to meet the written description requirement.

Furthermore, the claims are not just drawn to the entire polynucleotide and polypeptide sequences, rather the claims encompass fragments thereof wherein each fragment consists of at least eight consecutive amino acids from the respective allergenic proteins. There is no description of the fragments of nucleic acids that must

encode the hybrid polypeptide. The instant specification does not provide for a method for preparing a hybrid polypeptide comprising fragments of polynucleotide. The specification does not provide a teaching of the fragmented structure, showing that nucleic and amino acid fragments were isolated at the time the invention was made, thus there is no teaching of a preparation method. Applicants have failed to address these issues by pointing the support within the specification. Arguments about protective antibodies, or epitope sites fail to address the fact that there is no description of such methods of fragments, thus the rejection is maintained.

Applicants' urged that one of ordinary skill in the art armed with the instant specification, would understand the sequences used in the present invention. However, the standard is not that one would understand the sequences used in the present invention. To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., *Moba, B.V. v. Diamond Automation, Inc.*, 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed. Cir. 2003); *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d at 1563, 19 USPQ2d at 1116. No preparation method has been disclosed. Rather applicants' have disclosed the entire sequences but have failed to disclose a method for preparing a hybrid polypeptide comprising fragments consisting of at least eight consecutive amino acids from the respective allergenic proteins. There is no conception of a method for preparing a hybrid polypeptide comprising fragments thereof as claimed at the time of filing.

As stated earlier, the MPEP states that written description for a genus can be achieved by a representative number of species within a broad generic. It is unquestionable that the claims are broadly generic with respect all possible allergens

encompassed by the claims. The possible structural variations are limitless. It must not be forgotten that the MPEP states that if a biomolecule is described only by a functional characteristic, without any disclosed correlation between function and structure of the sequence, it is "not sufficient as a characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence." MPEP 2163.

Here, though the claims may recite some functional characteristics, the claims lack written description because there is no disclosure of a correlation between function and structure of the compounds beyond compounds disclosed in the examples in the specification. Moreover, the specification lack sufficient variety of species to reflect this variance in the genus since the specification does not provide any examples of derivatives. Furthermore, applicants have not taught what fragments will encode polynucleotides which are capable of encoding the polypeptide. There is no teaching of a representative fragment polynucleotide encoding a fragment of a polypeptide. There are no in vivo experiments. The specification is limited to the above mentioned timothy grass allergens. The written description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Accordingly, it is deemed that the specification fails to provide adequate written description for the genus of the claims and does not reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the entire scope of the claimed invention. In view of applicants' failure to explain the essential details the rejection is maintained.

Thus, in the absence of sequence information as claimed applicants arguments, declaration and amendments are not persuasive.

Applicants urge that the prior art does not teach hybrid polypeptides of known allergens, and that the instant invention does not concern itself with the detailed structural profile of the hybrid allergens so long as the functional characteristics claimed to of therapeutic interest is met. However,

"A written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula, [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials. *Fiers*, 984 F.2d at 1171, 25 USPQ2d at 1606; *In re Smythe*, 480 F.2d 1376, 1383, 178 USPQ 279, 284-85 (CCPA 1973) ("In other cases, particularly but not necessarily, chemical cases, where there is unpredictability in performance of certain species or subcombinations other than those specifically enumerated, one skilled in the art may be found not to have been placed in possession of a genus. . . ."). *Regents of the University of California v. Eli Lilly & Co.*, 43 USPQ2d 1398.

The MPEP further states that if a biomolecule is described only by a functional characteristic, without any disclosed correlation between function and structure of the sequence, it is "not sufficient characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence." MPEP 2163. The MPEP does state that for generic claim the genus can be adequately described if the disclosure presents a sufficient number of representative species that encompass the genus. MPEP 2163. If the genus has a substantial variance, the disclosure must describe a sufficient variety of species to reflect the variation within that genus. See MPEP 2163. Although the MPEP does not define what constitute a sufficient number of representatives, the Courts have indicated what do not constitute a representative number species to adequately describe a broad generic. In *Gostelli*, the Court determined that the disclosure of two chemical compounds within a subgenus did not

describe that subgenus. *In re Gostelli*, 872 F.2d at 1012, 10 USPQ2d at 1618.

Therefore applicants' arguments are not persuasive.

Applicants' assert that because they have provided a generic definition of fragments at pages 2-3 of the instant specification and because the entire sequence is known one of skill in the art would understand that they were in possession. For instance claim 49 fails to teach how to define fragments thereof with respect to which eight consecutive amino acids must be comprised therein to acquire the appropriate fragments. Neither the claims nor the specification teach how to obtain such fragments thereof. There is no guidance as to what amino acids may or may not be included without causing a detrimental effect to the fragments thereof as claimed. The claims broadly recite fragments thereof, therefore any fragment is being claimed, and no specific location requirement for particular amino acids is recited. Thus, the resulting fragments thereof could result in a functional fragment not taught and enabled by the specification. There is no written description of which eight amino acids must be comprised in the claimed hybrid polypeptide. This argument is not persuasive. With the exception of specifically recited sequences the skilled artisan cannot envision the detailed structure of the fragments thereof, thus conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. An adequate description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. The nucleic acid and amino acid fragment sequences themselves are required. See *Fiers v. Revel*,

25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process as is the case here. Applicants' specification point out fragments can exist, however there is no disclosure of even one representative fragment. Thus one of skill in the art could not immediately envision the claimed fragments. See, e.g., *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); *In re Ruschig*, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967) ("If n-propylamine had been used in making the compound instead of n-butylamine, the compound of claim 13 would have resulted. Appellants submit to us, as they did to the board, an imaginary specific example patterned on specific example 6 by which the above butyl compound is made so that we can see what a simple change would have resulted in a specific supporting disclosure being present in the present specification. The trouble is that there is no such disclosure, easy though it is to imagine it.") (emphasis in original); *Purdue Pharma L.P. v. Faulding Inc.*, 230 F.3d 1320, 1328, 56 USPQ2d 1481, 1487 (Fed. Cir. 2000) ("the specification does not clearly disclose to the skilled artisan that the inventors ... considered the ratio... to be part of their invention There is therefore no force to Purdue's argument that the written description requirement was satisfied because the

Art Unit: 1645

disclosure revealed a broad invention from which the [later-filed] claims carved out a patentable portion". Similarly, it appears that the instant case sets forth undisclosed fragments and asserts that these undisclosed fragments have some functional limitations. However, there is no actual disclosure of the claimed fragments. Moreover, the functional limitations do not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species.

Applicants' assert that they have conveyed with clarity to those skilled in the art that they were possession of the invention. However, at best applicants have shown that they were in possession of the entire sequence of timothy grass allergens, but applicants have not shown that they were in possession of fragments capable of inducing an antibody response. There is no disclosure of a highly conserved and immunogenic region in the plant allergen. Therefore, the specification lacks adequate support for the claims. Furthermore, *In The Reagents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the court held that a generic statement, which defines a genus of amino acids by only their functional activity, i.e., inducing an antibody response, does not provide an adequate description of the genus. The court indicated that while Applicants are not required to disclose every species encompassed by a genus, the description of a genus is achieved by the recitation of a representative number of DNA molecules, usually defined by a nucleotide sequence, falling within the scope of the claimed genus. At section B(1), the court states that "An adequate written description of a DNA...requires a precise definition, such as by structure, formula,

chemical name, or physical properties', not a mere wish or plan for obtaining the claimed chemical invention".

Currently the instant claims lack an adequate description of the fragments thereof, thus the descriptions are insufficient to support the claims as provided by the Interim Written Description Guidelines published in the June 15, 1998 Federal Register at Volume 63, Number 114, pages 32639-32645. Therefore, the full breadth of the claims fails to meet the written description provision of 35 USC 112, first paragraph and the rejection are maintained.

7. Claims 42-43 and 48-51 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

The rejection was on the grounds that neither the specification nor originally presented claims provides support for a hybrid polypeptide wherein upon administration into a patient induces IgE-blocking antibodies and has reduced allergenic activity compared with the respective wild-type allergens.

Applicant has pointed to pages 2, 7-9, 15; Example 2; and Figures 2, 5 and 7 of the instant specification and claims for support of the amendment which are drawn to the hybrid polypeptides. However it appears that the entire specification appears to fail to recite support for the generically claimed hybrid polypeptides. There is teaching of a

Art Unit: 1645

generic hybrid plant fusion polypeptide. Applicant has failed to point to a teaching associated with any isolated fragments or these fragments being comprised within a hybrid polypeptide. There is no teaching of a hybrid polypeptide comprising the generic components which induce an *in vivo* antibody response in any host. Therefore, it appears that there is no support in the specification. Therefore, applicants must specifically point to page and line number support for the identity of such generic hybrid polypeptides as recited by the new claims. Therefore, the claims incorporate new matter and the rejection is maintained since applicants' arguments are not persuasive.

8. Claims 42, 43, 45 and 48-51 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims recite the limitation "the respective wild-type allergens" in the claims. There is insufficient antecedent basis for this limitation in the claim. Appropriate clarification is required to overcome the rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. Claims 45-51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ball et al., (WO 95/34578) in view of Vrtala et al., (1996. J. Allergy Clin. Immun. Vol. 97(3): 781-787).

The claims are drawn to a pharmaceutical composition comprising one or more hybrid plant fusion allergens as immunotherapeutic agents, wherein said agents have been identified by a method comprising the steps of: (a) providing fusion allergens of naturally occurring plant allergens; (b) challenging an immunological model with said fusion allergens; (c) selecting as candidate immunotherapeutic agents, those fusion allergens which induce IgE-blocking antibodies and have reduced allergenic activity compared with the respective wild-type allergens. Furthermore, the claims are drawn to a hybrid allergen for treatment of IgE-mediated hypersensitivity, wherein said hybrid allergen is a fusion protein of two or more timothy grass pollen allergens.

Ball et al., teach the major grass pollen allergen Phl p1. The recombinant DNA molecule may contain a nucleotide sequence which codes for a polypeptide which would induce an antibody response (page 3 lines 20-25). The invention teaches a recombinant or synthetic protein or polypeptide comprising as an essential part Phl p1 (page 3 lines 33-35). The protein or polypeptide may be fused to an additional polypeptide, such as any other polypeptide that can be expressed as a fusion protein in prokaryotic or eukaryotic cells (page 4 lines 1-4). The invention also includes a recombinant DNA expression vector or cloning system (page 3 lines 26-30). Ball et al., while teaching that the Phl p1 can be part of a hybrid or fusion polypeptide does not specifically recite using another plant allergenic protein within the hybrid polypeptide.

Vrtala et al., teach grass pollen allergens belong to the potent elicitors of type I allergy (abstract). Vrtala et al., teach that DNA coding for three major timothy grass pollen allergens representing group I (Phl p1), group II (Phl p 2) and group V (Phl p 5) was known (page 781). The methods section teaches the construction of the expression plasmids for Phl p 1, Phl p 2 and Phl p 5 (page 782). cDNA clones were transcribed by polymerase chain reaction to DNA fragments coding for the mature allergens (page 782). Phl p 1 and Phl p 2, both of which contained ATG start codon in front of the coding region of the mature protein and genes were then inserted as fragments (page 782). The plasmids were transfected into *E.coli* host cells. The expression of the recombinant allergens in *E.coli* was also taught wherein cells were cultured, expressed, purified and thereby recovered (page 782).

Therefore it would have been prima facie obvious at the time of applicants' invention to modify the plant polypeptide as taught by Ball et al., to include a different plant allergen as taught by Vrtala et al., to create a hybrid plant fusion allergen wherein said allergen is a fusion protein of two or more timothy grass pollen allergens, since Ball et al., already teach the need to have a hybrid or fusion polypeptide. Ball et al., teach that plant allergenic proteins such as Phl p1 are amenable to being comprised within fusion proteins and/or hybrid polypeptides and can be fused to any other polypeptide that can be expressed as a fusion protein in prokaryotic or eukaryotic cells, while Vrtala et al., teach polypeptides that can be expressed in prokaryotic or eukaryotic cells, thus no more than routine skill would have been required to create a hybrid polypeptide comprising at least two plant allergens. Thus, there is a reasonable expectation of

success in using the Phl pI of Ball et al., and any other polypeptide such as the ones taught by Vrtala et al., when the prior art teaches that all of these plant allergens can be expressed as a fusion protein in prokaryotic or eukaryotic cells.

10. Claims 42 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ball et al., (WO 95/34578) in view of Vrtala et al., (1996. J. Allergy Clin. Immun. Vol. 97(3): 781-787). Both Ball et al., and Vrtala et al., have been discussed above.

The claims are drawn to a method of preparing hybrid plant fusion polypeptides comprising: (a) providing a polynucleotide encoding the plant fusion polypeptide; (b) introducing said polynucleotide into a host cell; (c) culturing the host cell obtained in b) under conditions such that the fusion polypeptide is expressed; and (d) recovering the expressed plant hybrid polypeptide from the cultured host cell; wherein said fusion polypeptide, upon administration into a patient induces IgE- blocking antibodies and has reduced allergenic activity compared with the respective wild-type allergens.

Therefore it would have been prima facie obvious at the time of applicants' invention to modify the method of preparing hybrid plant fusion polypeptides plant as taught by Ball et al., to include a different plant allergen as taught by Vrtala et al., to create a hybrid plant fusion allergen wherein said allergen is a fusion protein of two or more timothy grass pollen allergens, since Ball et al., already teach the need to have a hybrid or fusion polypeptides. Ball et al., teach that plant allergenic proteins such as Phl pI are amenable to being comprised within fusion proteins and/or hybrid polypeptides and can be fused to any other polypeptide that can be expressed as a fusion protein in

Art Unit: 1645

prokaryotic or eukaryotic cells, while Vrtala et al., teach polypeptides that can be expressed in prokaryotic or eukaryotic cells, thus no more than routine skill would have been required to create a hybrid polypeptide comprising at least two plant allergens. Thus, there is a reasonable expectation of success in using the Phl pl of Ball et al., and any other polypeptide to prepare the polypeptides such as the ones taught by Vrtala et al., when the prior art teaches that all of these plant allergens can be expressed as a fusion protein in host cells.

Conclusion

11. No claims allowed.
12. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ja-Na Hines whose telephone number is 571-272-0859. The examiner can normally be reached on Monday-Thursday and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on 571-272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ja-Na Hines
June 5, 2006


LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600